
Starliner astronauts recover after 9-month space stay
WASHINGTON: Butch Wilmore and Suni Williams, the U.S. astronauts left on the International Space Station last year by Boeing's troubled Starliner capsule, are on the up after returning to Earth in March, emerging from weeks of physical therapy to ramp up work with Boeing and various NASA programs.
'Right now, we're just coming off of the rehab portion of our return,' Wilmore, 62, told Reuters in an interview on Wednesday. 'Gravity stinks for a period, and that period varies for different people, but eventually you get over those neurovestibular balance type of issues.'
Wilmore and Williams, who last year set off for an eight-day Starliner test flight that swelled into a nine-month stay in space, have had to readapt their muscles, sense of balance and other basics of Earth living in a 45-day period standard for astronauts returning from long-term space missions.
The astronaut duo have spent at least two hours a day with astronaut strength and reconditioning officials within NASA's medical unit while juggling an increasing workload with Boeing's Starliner program, NASA's space station unit in Houston and agency researchers.
'It's been a little bit of a whirlwind,' Williams, 59, said in the interview. 'Because we also have obligations to all of the folks that we worked with.'
Williams said some of her post-spaceflight side effects were slower to clear up and she felt tired in late stages of recovery, as dozens of various muscles re-engaged. That made it hard for her to wake up as early in the mornings as she likes, until a little more than a week ago.
'Then I'm up at four in the morning, and I'm like, Aha! I'm back,' she said.
Wilmore had some issues with his back and neck before heading to space, being unable to turn his head all the way to the side, he said. That all went away in space where 'you don't have any stress on your body.'
When he returned in March, gravity greeted him with the neck pain he left on Earth.
'We're still floating in the capsule in the ocean, and my neck starts hurting, while we still hadn't even been extracted yet,' he said, laughing.
The human body, evolved over millions of years in the gravity of Earth's surface, was not meant for spaceflight.
The absence of gravity triggers an array of physical effects over time, such as muscle atrophy or cardiovascular shifts that can cause a chain reaction of other health changes. Confinement in a small space and higher solar radiation in space, without the protection of Earth's atmosphere, have other effects.
Starliner Problems
Propulsion system issues on Boeing's Starliner forced NASA to bring the capsule back without its crew last year and to fold the two astronauts into its normal, long-duration rotation schedule on the ISS.
Boeing, which has taken $2 billion in charges on its Starliner development, faces a looming decision by NASA to refly the spacecraft uncrewed before it carries humans again. Boeing spent $410 million to fly a similar uncrewed mission in 2022 after a 2019 testing failure.
Reflying Starliner uncrewed 'seems like the logical thing to do,' Williams said, drawing comparisons with Elon Musk's SpaceX and Russian capsules that flew uncrewed missions before putting humans aboard. She and NASA are pushing for that outcome, Williams added.
'I think that's the correct path,' said Williams, who is 'hoping Boeing and NASA will decide on that same course of action' soon.
Results from Starliner testing planned throughout the summer are expected to determine whether the spacecraft can fly humans on its next flight, NASA officials have said. (

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


The Star
2 hours ago
- The Star
Gilead commits to HIV prevention rollout for low-income countries despite funding uncertainty
(Reuters) -Gilead Sciences says it still plans to supply its twice-yearly injection for preventing HIV infection in low-income countries if it wins U.S. approval despite funding uncertainty over the Trump Administration's pullback in aid spending. Some AIDS experts, including activists and doctors, say the Gilead drug, lenacapavir, could help end the 44-year-old epidemic that infects 1.3 million people a year and is estimated by the World Health Organization to have killed more than 42 million. An FDA approval decision is expected by June 19 for lenacapavir, which proved to be nearly 100% effective at preventing HIV in large trials. If the Food and Drug Administration green lights the drug, and its view is seconded by the WHO, the shots could start to roll out early in 2026 to at least 2 million people in 18 low-income countries based on Gilead's agreement with the U.S. President's Emergency Plan for AIDS Relief (PEPFAR) and the Global Fund, a worldwide partnership targeting HIV, tuberculosis and malaria. Gilead agreed to provide lenacapavir at cost for two-to-three years while six generic drugmakers, which were granted licenses to make the medicine for low-income countries, ramp up production. Experts said a successful launch of a long-acting HIV prevention drug could help stall the epidemic. Until recently, the only pre-exposure prophylaxis (PrEP) options for people at high risk of infection were daily pills, requiring careful adherence to be effective. "You can foresee a day where there are no new HIV diagnoses. It doesn't happen if we only do this in the U.S.," Gilead Chief Commercial Officer Johanna Mercier said. "We need to make sure we have a global approach to this launch." PEPFAR being part of the effort is Gilead's intent and goal, Mercier said. "Unfortunately, if they're not part of that mix, our goal is still to meet that objective of 2 million people getting access." Wall Street has a close eye on lenacapavir, one of the highest-profile drugs to undergo FDA review since President Donald Trump named Robert F. Kennedy Jr. as health secretary and promised to upend the status quo. Most of the drug's profits are expected in the U.S., with annual sales reaching $1 billion by next year, according to analysts' estimates compiled by LSEG. 'INCREDIBLE DISMAY' Whether all of the agreed funding for low-income countries - most of which are in Africa - will come through is unclear. Countries that rely on aid are already reeling from funding cuts by the Trump Administration, including to PEPFAR, and AIDS researchers are bracing for the worst. The United Nations program on HIV/AIDS earlier this month said many HIV prevention programs supported by PEPFAR were stalled, although services for pregnant and breastfeeding women were technically exempt from the cuts. Peter Sands, executive director of the Global Fund, told Reuters the group intends to fund as much of the lenacapavir rollout as possible, but it will need to start slowly. "It's not just the uncertainty over PEPFAR's funding that's an issue, but the uncertainty over our funding," Sands said, adding that the group's first priority is treating people already infected with the deadly virus. Much will depend on the success of the Global Fund's effort to raise $18 billion to fund its work from 2027-2029. The U.S. is its largest donor, committing $6 billion in the previous funding round. It is unclear what the U.S. may provide this round, or whether other big governments will step up. UNAIDS estimates that the permanent discontinuation of HIV prevention and treatment programs supported by PEPFAR would lead to an additional 6.6 million new HIV infections between 2025 and 2029. The U.S. State Department, which oversees PEPFAR, did not respond to a request for comment. Gilead declined to comment on its manufacturing cost for lenacapavir, whose U.S. price is likely to be on par with current preventive medications at around $25,000 per year. ViiV Healthcare's Apretude, an injection given every two months, costs about 124.20 pounds ($168) in low- and middle-income countries. Mitchell Warren, executive director of the AIDS nonprofit AVAC, estimates the eventual annual cost at $100-$120. The lower the price, the more people who could receive it, he said. Warren said PEPFAR could still participate, and others may come forward. The Gates Foundation and the Children's Investment Fund Foundation are "actively involved in all of these conversations," he said, as is the Elton John AIDS Foundation. Linda-Gail Bekker of the University of Cape Town, who led lenacapavir clinical trials in South Africa and Uganda, said she was elated when she first saw the findings. "The huge feeling I have now is one of incredible dismay," said Bekker of uncertainty over the Trump administration's commitment to PEPFAR and HIV prevention in poor nations. "It felt like the stars were aligning, and one of the stars has fallen out of the sky." (Reporting by Julie Steenhuysen in Chicago and Deena Beasley in Los Angeles; additional reporting by Jennifer Rigby in London; editing by Caroline Humer and Bill Berkrot)


The Sun
10 hours ago
- The Sun
Musk targets 2026 for first Starship Mars test flight
LOS ANGELES: Two days after the latest in a string of test-flight setbacks for his big new Mars spacecraft, Starship, Elon Musk said on Thursday he foresees the futuristic vehicle making its first uncrewed voyage to the red planet at the end of next year. Musk presented a detailed Starship development timeline in a video posted online by his Los Angeles area-based rocket company, SpaceX, a day after departing the administration of U.S. President Donald Trump as head of a tumultuous campaign to slash government bureaucracy. The billionaire entrepreneur had said earlier that he was planning to scale back his role in government to focus greater attention on his various businesses, including SpaceX and electric car and battery maker Tesla Inc. Musk acknowledged that his latest timeline for reaching Mars hinged on whether Starship can accomplish a number of challenging technical feats during its flight-test development, particularly a post-launch refueling maneuver in Earth orbit. The end of 2026 would coincide with a slim window that occurs once every two years when Mars and Earth align around the sun for the closest trip between the two planets, which would take seven to nine months to transit by spacecraft. Musk gave his company a 50-50 chance of meeting that deadline. If Starship were not ready by that time, SpaceX would wait another two years before trying again, Musk suggested in the video. The first flight to Mars would carry a simulated crew consisting of one or more robots of the Tesla-built humanoid Optimus design, with the first human crews following in the second or third landings. NASA is currently aiming to return humans to the surface of the moon aboard Starship as early as 2027 - more than 50 years after its last manned lunar landings of the Apollo era - as a stepping stone toward ultimately launching astronauts to Mars sometime in the 2030s. Musk, who has advocated for a more Mars-focused human spaceflight program, has previously said he was aiming to send an unmanned SpaceX vehicle to the red planet as early as 2018 and was targeting 2024 to launch a first crewed mission there. The SpaceX founder was scheduled to deliver a live webcast presentation billed as 'The Road to Making Life Multiplanetary' from the company's Starbase, Texas, launch site on Tuesday night, following a ninth test flight of Starship that evening. But the speech was canceled without notice after Starship spun out of control and disintegrated in a fireball about 30 minutes after launch and roughly halfway through its flight path without achieving some of its most important test goals. Two preceding test flights in January and March failed in more spectacular fashion, with the spacecraft blowing to pieces on ascent moments after liftoff, raining debris over parts of the Caribbean and forcing scores of commercial jetliners to change course as a precaution. Musk shrugged off the latest mishap on Tuesday with a brief post on X, saying it produced a lot of 'good data to review' and promising a faster launch 'cadence' for the next several test flights.


The Sun
10 hours ago
- The Sun
Musk aiming to send uncrewed Starship to Mars by end of 2026
LOS ANGELES: Two days after the latest in a string of test-flight setbacks for his big new Mars spacecraft, Starship, Elon Musk said on Thursday he foresees the futuristic vehicle making its first uncrewed voyage to the red planet at the end of next year. Musk presented a detailed Starship development timeline in a video posted online by his Los Angeles area-based rocket company, SpaceX, a day after departing the administration of U.S. President Donald Trump as head of a tumultuous campaign to slash government bureaucracy. The billionaire entrepreneur had said earlier that he was planning to scale back his role in government to focus greater attention on his various businesses, including SpaceX and electric car and battery maker Tesla Inc. Musk acknowledged that his latest timeline for reaching Mars hinged on whether Starship can accomplish a number of challenging technical feats during its flight-test development, particularly a post-launch refueling maneuver in Earth orbit. The end of 2026 would coincide with a slim window that occurs once every two years when Mars and Earth align around the sun for the closest trip between the two planets, which would take seven to nine months to transit by spacecraft. Musk gave his company a 50-50 chance of meeting that deadline. If Starship were not ready by that time, SpaceX would wait another two years before trying again, Musk suggested in the video. The first flight to Mars would carry a simulated crew consisting of one or more robots of the Tesla-built humanoid Optimus design, with the first human crews following in the second or third landings. NASA is currently aiming to return humans to the surface of the moon aboard Starship as early as 2027 - more than 50 years after its last manned lunar landings of the Apollo era - as a stepping stone toward ultimately launching astronauts to Mars sometime in the 2030s. Musk, who has advocated for a more Mars-focused human spaceflight program, has previously said he was aiming to send an unmanned SpaceX vehicle to the red planet as early as 2018 and was targeting 2024 to launch a first crewed mission there. The SpaceX founder was scheduled to deliver a live webcast presentation billed as 'The Road to Making Life Multiplanetary' from the company's Starbase, Texas, launch site on Tuesday night, following a ninth test flight of Starship that evening. But the speech was canceled without notice after Starship spun out of control and disintegrated in a fireball about 30 minutes after launch and roughly halfway through its flight path without achieving some of its most important test goals. Two preceding test flights in January and March failed in more spectacular fashion, with the spacecraft blowing to pieces on ascent moments after liftoff, raining debris over parts of the Caribbean and forcing scores of commercial jetliners to change course as a precaution. Musk shrugged off the latest mishap on Tuesday with a brief post on X, saying it produced a lot of 'good data to review' and promising a faster launch 'cadence' for the next several test flights.